Dr. Reddy's Laboratories share price rose nearly 3 percent on September 2 after the company launched the generic equivalent of Revlimid (lenalidomide) capsules in the Canadian market.
Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada.
Catch all the market action on our live blog
"Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada's Multiple Myeloma and Myelodysplastic Syndrome (MDS) patient population," said Vinod Ramachandran, Ph.D., Vice President and General Manager, Dr. Reddy's Laboratories Canada.
"Along with this important launch, we are pleased to introduce our Reddy2Assist Platform, which provides convenient one-stop access to assist prescribers and pharmacists with qualification requirements for patients, as well as patient on boarding and registration via web portal, telephone or fax," he added.
Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs.
At 09:29 hrs, Dr Reddy’s Laboratories was quoting at Rs 4,898.85, up Rs 134.90, or 2.83 percent on the BSE.
The share touched a 52-week high of Rs 5,613.65 and a 52-week low of Rs 4,135.90 on 07 July, 2021 and 19 March, 2021, respectively.
Currently, it is trading 12.73 percent below its 52-week high and 18.45 percent above its 52-week low.